Tripling the dose of Novo Nordisk’s obesity treatment led to increased weight loss in patients during a clinical trial, as the company seeks to broaden treatment options and stay competitive with Eli Lilly’s rival drug.
Semaglutide, marketed as Wegovy for weight loss and Ozempic to treat diabetes, delivered promising results in two late-stage clinical trials testing a 7.2mg dose of the drug. The maximum approved dose is currently 2.4mg
Patients in the larger of the two trials lost an average of 19 per cent of their body weight after 72 weeks, compared with 16 per cent on the 2.4mg dose and 4 per cent on placebo.
您已閱讀21%（619字），剩余79%（2294字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。